Home/ Stocks/ KROS

Keros Therapeutics, Inc. Common Stock

KROS XNAS

$11.15 +0.50 (+4.69%) ▲ 15-min delayed

Open

$10.74

High

$11.26

Low

$10.57

Volume

319.6K

Market Cap

$211.16M

About Keros Therapeutics, Inc. Common Stock

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 92 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$0	$-28,710,000	$-1.45
Q1 2026	$32.0K	$-23,708,000	$-1.21
FY 2025	$243.86M	$87.01M	$2.34
Q3 2025	$14.12M	$-7,280,000	$-0.18

Earnings & Analyst Ratings

Next Earnings: Tue, Nov 3, 2026

Calendar →

Related Market News

No specific coverage for KROS yet. Check out our latest market news or earnings calendar.

Get KROS Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Keros Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.